



Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany

Daniel Schmidt¹ · Christian Kollan¹ · Barbara Bartmeyer¹ · Viviane Bremer¹ · Tim Schikowski¹ · Martin Friebe¹ · Sven Schellberg² · Stefan Scholten³ · Markus Bickel⁴ · Nikola Hanhoff⁵ · Robin Rösenberg⁵ · Knud Schewe⁵ · The NEPOS study group

Received: 25 June 2022 / Accepted: 29 August 2022
© The Author(s) 2022

Abstract

Introduction Objectives of this study, as part of a nation-wide HIV pre-exposure prophylaxis (PrEP) evaluation project, were to determine the incidence of infections with HIV, chlamydia, gonorrhea, syphilis, hepatitis A/B/C in persons using PrEP, and to describe the health care funded PrEP use in Germany. Additionally, factors associated with chlamydia/gonorrhea and syphilis infections were assessed.

Methods Anonymous data of PrEP users were collected at 47 HIV-specialty centers from 09/2019–12/2020. Incidence rates were calculated per 100 person years (py). Using longitudinal mixed models, we analyzed risk factors associated with sexually transmitted infections (STIs).

Results 4620 PrEP users were included: 99.2% male, median age 38 years (IQR 32–45), 98.6% men who have sex with men (MSM). The median duration of PrEP exposure was 451 days (IQR 357–488), totaling 5132 py. Four HIV infections were diagnosed, incidence rate 0.078/100py (95% CI 0.029–0.208). For two, suboptimal adherence was reported and in the third case, suboptimal adherence and resistance to emtricitabine were observed. One infection was likely acquired before PrEP start. Incidence rates were 21.6/100py for chlamydia, 23.7/100py for gonorrhea, 10.1/100py for syphilis and 55.4/100py for any STI and decreased significantly during the observation period. 65.5% of syphilis, 55.6% of chlamydia and 50.1% of gonorrhea cases were detected by screening of asymptomatic individuals. In a multivariable analysis among MSM younger age, PrEP start before health insurance coverage and daily PrEP were associated with greater risk for chlamydia/gonorrhea. Symptom triggered testing and a history of STI were associated with a higher risk for chlamydia/gonorrhea and syphilis. A significantly lower risk for chlamydia/gonorrhea and syphilis was found for observations during the COVID-19 pandemic period.

Conclusions We found that HIV-PrEP is almost exclusively used by MSM in Germany. A very low incidence of HIV infection and decreasing incidence rates of STIs were found in this cohort of PrEP users. The results were influenced by the SARS-CoV-2 pandemic. Rollout of PrEP covered by health insurance should be continued to prevent HIV infections. Increased PrEP availability to people at risk of HIV infection through the elimination of barriers requires further attention. Investigation and monitoring with a longer follow-up would be of value.

Keywords Human immunodeficiency virus (HIV) · HIV pre-exposure prophylaxis (PrEP) · Sexually transmitted infections (STI) · Germany · Health insurance coverage

Abbreviations

CI	Confidence interval
COVID-19	Coronavirus disease 2019
Dagnä e.V.	Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter e.V. (German)

Members of The NEPOS study group are listed in the Acknowledgement section.

✉ Daniel Schmidt
SchmidtD@rki.de

Extended author information available on the last page of the article

DISCOVER	Study to evaluate the safety and efficacy of emtricitabine and tenofovir alafenamide (F/TAF) fixed-dose combination once daily for pre-exposure prophylaxis in men and transgender women who have sex with men and are at risk of HIV-1 infection
EPIC-NSW	Expanded PrEP implementation in communities in New South Wales
EvE-PrEP	Evaluation der Einführung der HIV-Präexpositionsprophylaxe als Leistung der Gesetzlichen Krankenversicherung (German)
HIV	Human immunodeficiency virus
IPERGAY	Intervention préventive de l'exposition aux risques avec et pour les GAYs (French)
iPrEX OLE	“Iniciativa Profilaxis Pre-Exposición” (Spanish), open label extension
IQR	Interquartile range
MSM	Men who have sex with men
NEPOS	National Evaluation of PrEP Outcomes and STIs
OR	Odds Ratio
PrEP	Pre-exposure prophylaxis
PREVENIR	Prevention of HIV in “Île-de-France”
PROUD	Pre-exposure option for reducing HIV in the United Kingdom
py	Person years
RKI	Robert Koch Institute
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus-2
STI	Sexually transmitted infection
TDF/FTC	Tenofovir disoproxil fumarate and emtricitabine

Introduction

Infection with the human immunodeficiency virus (HIV) remains globally endemic with 1.5 million new infections annually despite continued advancements in its management, treatment, and prophylaxis [1]. In Germany, HIV transmission remains an issue despite prophylactic measures, and a knowledgeable men who have sex with men (MSM) population which is the largest affected group. Of the estimated 91 400 people living with HIV in Germany at the end of 2020, an estimated 90% (~ 81 900) were diagnosed with HIV, 97% (~ 79 300) were receiving antiretroviral treatment and 96% (~ 76 500) were virally suppressed [2, 3]. Whereas prevention historically focused on condom use and safe injection practices, the approval of the antiviral agents tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for HIV pre-exposure prophylaxis (PrEP) has added a valuable

tool for prevention in certain populations. Efficacy has been reported as high as 95% in MSM [4]. Unfortunately, similar results were not observed in women [5]. Since the efficacy of PrEP is highly correlated with adherence, an evaluation in the routine clinical care setting would provide further information on PrEP use and outcomes [6].

Although the use of PrEP significantly reduces the risk of HIV transmission, it may change sexual behavior resulting in an elevated risk for the transmission of other sexually transmitted infections (STIs) and even HIV [7–9]. On the other hand, PrEP access under medical supervision offers an opportunity for counselling, regular STI screening and appropriate treatment [7]. Earlier diagnosis of HIV infection and STIs and prompt treatment in turn may limit onward transmission.

PrEP was approved in Germany in 2016 and available initially on a self-paying basis [10]. As a result, it was frequently obtained from informal sources outside of the health care system and hence without adequate testing for HIV and other STIs, counselling and monitoring of side effects. Since September 2019, PrEP and its care by a certified and (HIV-) specialized physician is covered by the statutory health care system in Germany [11]. A previous analysis of PrEP use in Germany was based on prescription data and surveys among MSM and estimated a total of 15 600 to 21 600 PrEP users by the end of June 2020 [12]. However, further information on the characteristics of PrEP users, mode of PrEP use and incidences of HIV and other STI over time is required.

The uptake and outcome of PrEP use after introduction of coverage by the German statutory health insurance as well as any effects on the incidence of STIs were evaluated through a nation-wide study in Germany (“EvE-PrEP”) [13–18]. The evaluation consisted of several independent studies. The objectives of the NEPOS (National Evaluation of PrEP Outcomes and STIs) study, as part of the EvE-PrEP project, were to determine the incidence of infections with HIV, chlamydia, gonorrhea, syphilis, hepatitis A/B/C in persons using PrEP, and to describe the health care funded PrEP use in Germany. Additionally, factors associated with infections with chlamydia/gonorrhea and syphilis were assessed.

Methods

Study population and data collection

The NEPOS study was conducted by the Robert Koch Institute (RKI) in collaboration with the German association of physicians in HIV care (dagnä e.V.). All HIV-specialty care centers were invited to participate. The study was a retrospective longitudinal analysis of randomly selected PrEP users. The maximal number of PrEP users that could be documented in the study was set at 5000 for budgetary reasons.

To ensure that the study sample is representative for the German PrEP using population, the centers were allocated a defined quota on the basis of their PrEP using population in reference to that of all participating centers. The randomization process at each center was performed at the discretion of the participating center.

Data were collected anonymously using an electronic reporting form in the first quarter of 2021 retrospectively for the time-period of September 2019 through December 2020. Date of individual PrEP initiation before September 2019 was documented if persons started PrEP before the observation period. STI with chlamydia, gonorrhea or syphilis 6 months prior to PrEP initiation were also documented (patient file or self-reported).

The study centers entered the data into the electronic reporting form from routine patient files. Data included patient characteristics (age, gender), PrEP use (indication, starting date, daily vs. intermittent/on-demand use as well as any interruption or discontinuation dates and reasons), testing for and potential diagnosis of HIV, hepatitis and STI, as well as hepatitis A and B antibody status. Duration of PrEP use was calculated as the number of days between PrEP start and end of follow-up, the latter defined by either PrEP discontinuation or the end of the study, 31/12/2020. Aside from HIV infection, STI included chlamydia, gonorrhea and syphilis. Newly diagnosed viral hepatitis included A, B and C. The observation period was divided into five time intervals: First September through December 2019, then four quarters in 2020 (2020q1–2020q4). Gonorrhea, chlamydia and syphilis were counted for each time interval, HIV and hepatitis with a date of diagnosis.

STI, HIV and hepatitis incidence rates

Testing for HIV and STIs was performed in all centers as recommended by the German/Austrian PrEP guidelines [19]. In accordance with Ong et al., STI diagnosis within 90 days of PrEP initiation was defined as baseline prevalence [20]. Incidence rates were determined for STIs occurring while on PrEP and calculated by dividing the number of STI cases by the duration of PrEP exposure per time interval as per 100 person years (py). For incidence rates of infections with hepatitis and HIV, the duration of PrEP exposure in the observation period to the date of diagnosis was calculated as person-time. More than one positive test for a certain STI within one time interval was counted as one result. This procedure was chosen, because STIs were reported as the number of infections per time interval without the precise date of diagnosis. Additionally, because these events were rare, a sensitivity analysis showed a negligible effect of multiple infections with the same STI within a single time interval on STI incidence rates. It was predefined that PrEP was only considered interrupted or discontinued if stopped for longer

than 4 weeks. As an additional indicator for either intermittent/on-demand PrEP use or suboptimal adherence to a documented daily PrEP, PrEP pill coverage was calculated using the number of pills prescribed divided by the number of days on PrEP. In case of a surplus of pills the number of pills were adjusted to the total duration of PrEP exposure to calculate the average PrEP pill coverage, assuming that for daily PrEP a maximum of one pill per day is taken (e.g. a prescription of $5 \times 90 = 450$ pills over a duration of 365 days results in a PrEP pill coverage of 1.23 which for the calculation of the average PrEP pill coverage was adjusted to 1.0).

Statistical analysis

Univariable and multivariable longitudinal multilevel mixed-effects logistic regression corrected for the study centers as random intercept were used to analyze risk factors associated with infections with chlamydia/gonorrhea and syphilis. The analysis was performed among all MSM with/without other risk factors being tested in the respective time interval adjusted for age, PrEP use (intermittent/on-demand vs. daily), PrEP interruptions, PrEP discontinuations, PrEP duration, PrEP start before statutory health insurance coverage, infections with Hepatitis or HIV, other STI than the one analyzed, STI history (any STI yes/no) in the past 6 months before PrEP start, the number of STI tests, observation before (2019q4, 2020q1) or within (2020q2, 2020q3, 2020q4) the COVID-19 pandemic period.

Sensitivity analysis of loss to follow-up

In a sensitivity analysis, we analyzed persons without any event related to PrEP use (testing, diagnosis, treatment of STI, HIV, Hepatitis, or PrEP prescriptions) for at least two quarters before their last event to calculate a "loss to follow-up" rate for those without documentation of PrEP discontinuation or interruption.


Data were collected anonymously using an electronic reporting form programmed in C++. Data were stored and the dataset prepared using a MS-SQL server. Statistical analysis was performed using STATA Version 17. Figures were produced using Gfk RegioGraph and Microsoft Excel (Office 2019).

Results

Forty-seven German HIV-specialty care centers participated in the study and provided representation of PrEP use as a whole from both a geographical and a diversity perspective (Fig. 1).

4620 PrEP users were randomly selected to be documented in this study. Nearly all (99.2%) were male, median

Fig. 1 Distribution of participating study centers in Germany



Study centers N = 47

age was 38 years (IQR 32–45), 98.6% were MSM of whom 10.6% had additional risk factors. Of the 39 PrEP users who were not male, 17 were female, 16 transgender and four non-binary gender. Characteristics are shown in Table 1. The majority of cases ($n = 1638$, 35.5%) were documented in Berlin, which also reflects the pre-dominant location of current PrEP use.

PrEP use

The median duration of PrEP exposure within the period of observation (September 2019–December 2020) was 451 days (IQR 357–488), totaling 5132 py. More than one-half of PrEP users had started PrEP prior to September 2019 ($n = 2466$, 53.4%). Taking this into consideration,

Table 1 Characteristics of the study population

Total study population 4620	<i>N</i> (%)
Age (years)	
16–19	3 (0.1%)
20–29	715 (15.5%)
30–39	1864 (40.3%)
40–49	1233 (26.7%)
50–59	669 (14.5%)
≥ 60	136 (2.9%)
Gender	
Male	4581 (99.2%)
Female	17 (0.4%)
Diverse	4 (0.1%)
Trans (m-> f)	12 (0.3%)
Trans (f-> m)	6 (0.1%)
PrEP indication	
MSM	4065 (88.0%)
MSM and other high risk contacts	294 (6.4%)
MSM and HIV-discordant couple	142 (3.1%)
Other high-risk contacts	33 (0.7%)
MSM and IDU	25 (0.5%)
HIV-discordant couple	23 (0.5%)
IDU	1 (0.0%)
Other combinations	33 (0.7%)
Missing	4 (0.1%)
PrEP type of administration	
Daily	3737 (80.9%)
On Demand	874 (18.9%)
Missing	9 (0.2%)
PrEP start prior to 01/09/2019	
Yes	2466 (53.4%)
No	2106 (45.6%)
Unknown/missing	48 (1.0%)
PrEP interruption	
No	4159 (90.0%)
Yes	462 (10.0%)
PrEP discontinuation	
No	4012 (86.8%)
Yes	608 (13.2%)
Calculated PrEP pill coverage—PrEP prescriptions/ time for all participants	
< 0.75	1069 (23.1%)
0.75–1.24	3184 (68.9%)
≥ 1.25	341 (7.9%)
Missing	26 (0.6%)
Hepatitis A immunity	
Yes	3358 (72.7%)
Incomplete	201 (4.4%)
No	299 (6.5%)
Not determined/missing	762 (16.5%)

Table 1 (continued)

Total study population 4620	<i>N</i> (%)
Hepatitis B immunity	
Yes	3664 (79.3%)
Incomplete	336 (7.3%)
No	329 (7.1%)
Not determined/missing	291 (6.3%)
STI in the 6 months prior to PrEP start	
Chlamydia	231 (5.0%)
Gonorrhea	261 (5.6%)
Syphilis	234 (5.1%)
Multiple STI before PrEP start	196 (4.2%)
No STI in the 6 months prior to PrEP start	2777 (60.1%)
Unknown/missing	921 (19.9%)

the median duration of PrEP exposure was 500 days (IQR 388–766), totaling 7353 py. Intermittent/on-demand PrEP was documented for 18.9%. In all, the average number of days of PrEP as prescribed divided by the number of days on PrEP (PrEP pill coverage) was 0.85 (SD=0.23). Almost one-third ($n = 1460$, 31.6%) had a calculated PrEP pill coverage of less than 85%, which reflected both intermittent/on-demand PrEP use as well as a documented daily PrEP with lower adherence. The average PrEP pill coverage by mode of PrEP intake was 0.91 (SD=0.16) for persons with PrEP prescribed for daily intake and 0.58 (SD=0.28) for persons using PrEP intermittent/on-demand.

Ten percent of PrEP users had at least one PrEP interruption with a median duration of 93 days (IQR 58–148) with the first interruption after a median of 238 days (IQR 119–458) after PrEP start. PrEP discontinuations were documented for 13.2% after a median time of 275 days (IQR 142–478). Reasons for PrEP discontinuation or interruption were mainly SARS-CoV-2 related (38.2% of responses; 47.7% of persons); also, PrEP interruptions were highest in March and April 2020 (49.5% of all interruptions), at the





Fig. 2 Proportion of PrEP interruptions over time from September 2019 to December 2020



* Other (included time consuming, HIV infection, medical interaction, costs, doubt of effectiveness)

Fig. 3 Primary reasons for discontinuing or interrupting PrEP. 905 reasons were documented for 725 individuals, combinations of reasons were categorized accordingly (multiple answers possible; proportion based on 905 reasons)

time of the first COVID-19 lock-down (Figs. 2, 3). Whereas adverse reactions were rarely reported as the reason for PrEP discontinuation or interruption (3.3% of responses; 4.1% of persons) (Fig. 3).

Twelve percent ($n = 555$) did not have any event related to PrEP use (testing, diagnosis, treatment of STI, HIV, Hepatitis, or PrEP prescriptions) for at least two quarters before their last event, 84.5% ($n = 469$) of whom did not indicate PrEP discontinuation or interruption.

HIV

During the observation period, four persons became diagnosed with HIV infection while on PrEP (MSM, age 26–33), accounting for 0.087% and an incidence rate of 0.078/100py (95% CI 0.029–0.208). HIV infections were diagnosed on day 32, 167, 270 and 295 after start of study observation, which corresponds to day 32, 167, 595 and 598 after PrEP start. For two individuals, PrEP on demand was documented, for the other two daily PrEP. The reason for infection in two cases was reported to be suboptimal adherence. In the third case, calculated PrEP pill coverage was 0.6 and resistance to FTC was observed. The fourth person, diagnosed on day 32 after PrEP initiation, reported condomless rectal intercourse a few days prior to PrEP start.

Three of these patients were also diagnosed with other STIs. Two of the individuals had presented with a syphilis infection in the previous 6 months before PrEP start and three had other STIs during the observation period (Table 2).


STI—chlamydia, gonorrhoea, syphilis

Twenty percent of the study population were reported to have had an STI in the 6 months prior to PrEP start. The baseline STI prevalences were 7.01% (95% CI 6.05–8.09)

Table 2 Description of persons with HIV infections

Age	PrEP indi- cation	PrEP use	Quotient Pills/days PrEP	PrEP start	PrEP Interrup- tion (definition 4 weeks)	Last HIV negative test	HIV posi- tive test	Days from PrEP start to HIV infec- tion	Days from observation start to HIV infection	Reasons for HIV infec- tion	HIV resist- ance	STI during PrEP use	STI before PrEP start
26	MSM	On demand	0.71	05.12.2019	No	11.03.2020	20.05.2020	167	167	PrEP on demand with poor adherence	No	No	No
27	MSM	Daily	1.82	06.01.2020	No	17.12.2019	07.02.2020	32	32	HIV risk before PrEP start	No	Gonorrhoe 2019q4	Unknown
33	MSM	On demand	0.75	01.02.2019	Yes 01.09.2019 –03.02.2020	27.01.2020	18.09.2020	595	270	PrEP on demand with poor adherence	Other resistance not TDF/FTC associated	Syphilis 2019q4	Syphilis
33	MSM	Daily	0.60	02.11.2018	No	23.01.2020	22.06.2020	598	295	Not documented	FTC resistance (M184IV)	Chlamydia 2020q1	Syphilis

Fig. 4 STI incidence rate, positivity rate and number of tests among German PrEP users over time from September 2019 to December 2020



* Number of tests were adjusted to a quarter for the time interval 09/2019-12/2019

Table 3 Incidence of STI infections on PrEP over time from September 2019 to December 2020

	09/2019–12/2019	2020q1	2020q2	2020q3	2020q4	Overall
Persons	1932	3842	4327	4226	4099	4620
Person years (PY) at risk	592.25	931.34	1054.07	1048.84	1017.91	4644.41
Positive results chlamydia	166	220	191	238	186	1101
Chlamydia incidence rate	28.03/100py	23.62/100py	18.12/100py	22.69/100py	18.27/100py	21.55/100py
95% CI	(24.07–32.63)	(20.7–26.96)	(15.72–20.88)	(19.98–25.77)	(15.83–21.1)	(20.24–22.93)
<i>P</i> value comparison*	Ref.	0.0957	< 0.0001	0.0364	0.0001	
Positive results gonorrhoea	185	257	198	227	235	1102
Gonorrhoea incidence rate	31.24/100py	27.59/100py	18.78/100py	21.64/100py	23.09/100py	23.73/100py
95% CI	(27.04–36.08)	(24.42–31.18)	(16.34–21.59)	(19.00–24.65)	(20.32–26.24)	(22.35–25.17)
<i>P</i> value comparison*	Ref.	0.1982	< 0.0001	0.0002	0.0020	
Positive results syphilis	76	100	113	83	96	468
Syphilis incidence rate	12.83/100py	10.74/100py	10.72/100py	7.91/100py	9.43/100py	10.08/100py
95% CI	(10.25–16.07)	(8.83–13.06)	(8.92–12.89)	(6.38–9.81)	(7.72–11.52)	(9.18–11.03)
<i>P</i> value comparison*	Ref.	0.2408	0.2248	0.0021	0.0440	
Positive results any STI	427	577	502	548	517	2571
Any STI incidence rate	72.10/100py	61.95/100py	47.62/100py	52.25/100py	50.79/100py	55.36/100py
95% CI	(65.42–79.27)	(57.00–67.22)	(43.55–51.98)	(47.96–56.81)	(46.51–55.36)	(53.24–57.54)
<i>P</i> value comparison*	Ref.	0.0174	< 0.0001	< 0.0001	0.0002	

**P* value comparison for the incidence rates between quarters in reference to 09/2019–12/2019, *P* value obtained using the χ^2 -statistic [49]

for chlamydia, 6.62% (95% CI 5.68–7.66) for gonorrhoea and 3.63% (95% CI 2.93–4.44) for syphilis.

Incidence rates during PrEP use in the observation period were 21.55/100py (95% CI 20.24–22.93) for chlamydia, 23.73/100py (95% CI 22.35–25.17) for gonorrhoea and 10.08/100py (95% CI 9.18–11.03) for syphilis. The total incidence rate of any STI in our cohort was 55.36/100py (95% CI 53.24–57.54). The incidence per time period of any STI significantly decreased over time. Incidence rates over time are shown in Fig. 4 and Table 3 and were highest for all three infections in the first time interval (September–December 2019). Incidence rates already decreased in the first quarter of 2020. While the lowest incidence rates were seen in the second quarter of 2020 for both chlamydia and gonorrhoea, it was lowest for syphilis in the third quarter. A rise in the incidence of gonorrhoea and syphilis was again seen towards the fourth quarter of 2020 despite fewer tests. Overall, a significant reduction of 34.8% was found for chlamydia and of 26.1% for gonorrhoea over the course of the observation period, as well as a reduction of 38.4% for syphilis from the first time interval through the third quarter of 2020. The total incidence of any STI showed a significant reduction of 29.6% over the course of the observation period.

Over one-third of the study participants ($n = 1728$, 37.4%) were reported to have had at least one STI in the observation period. During the study, 1203 tests for chlamydia were positive in 21.0% (971/4620 persons). For gonorrhoea and syphilis, these were 1324 positive tests in 21.4% (987/4620

persons) and 602 positive tests in 8.9% (409/4620 persons), respectively. More than one infection with chlamydia, gonorrhoea or syphilis were reported for 4.2% (194/4620 persons), 5.2% (238/4620 persons) and 1.6% (75/4620 persons), respectively. Sixty-seven individuals (1.5%) had infections with all three pathogens over the course of the observation.

Syphilis was tested for more frequently than chlamydia/gonorrhoea (18 598 vs. 12 789 tests). (Fig. 2) The median number of tests per individual was three for chlamydia/gonorrhoea (IQR 2–4, range 0–20) and four for syphilis (IQR 3–5, range 0–20). More than three-quarters had at least three tests for syphilis ($n = 3630$, 78.6%), while 43.6% ($n = 2016$) had at least three tests for chlamydia/gonorrhoea. No testing for chlamydia/gonorrhoea was documented for 22.6% ($n = 1046$), while no testing for syphilis was reported for 1.6% ($n = 76$). During the observation period, the lowest number of tests for chlamydia and gonorrhoea were found in the second and fourth quarter of 2020 ($n = 2186$ and $n = 2171$, respectively) and for syphilis in the fourth quarter of 2020 ($n = 3183$).

The positivity rate remained relatively constant with a mean of 9.2%, 9.9% and 3.0% for chlamydia, gonorrhoea and syphilis, respectively (Fig. 2). While 65.5% of syphilis diagnosis were detected by screening of asymptomatic individuals, these were 55.6% for chlamydia and 50.1% for gonorrhoea. The proportion of screening tests of asymptomatic individuals in view of all tests was 84.1% (10 759/12 789) for chlamydia/gonorrhoea and 94.9% (17 645/18 598) for syphilis.

The multivariable analysis of risk factors associated with chlamydia/gonorrhoea infections among MSM showed

a significantly higher risk for persons 16 to 29 years of age (OR 1.28, 95% CI 1.10–1.48), with PrEP start before statutory health insurance coverage (OR 1.23, 95% CI 1.06–1.43), with an STI history in the 6 months before PrEP start (OR 1.53, 95% CI 1.35–1.74) or an unknown STI history (OR 1.41, 95% CI 1.21–1.65), and with a higher number of symptom triggered tests for chlamydia/gonorrhea (OR 1.91, 95% CI 1.80–2.03). A significantly lower risk for infections with chlamydia/gonorrhea was found for persons 40–49 years of age (OR 0.77, 95% CI 0.68–0.88) or 50–59 years of age (OR 0.65, 95% CI 0.54–0.79), with intermittent/on-demand PrEP use (OR 0.78, 95% CI 0.66–0.91), and with a higher number of tests for chlamydia/gonorrhea when persons were asymptomatic (OR 0.93, 95% CI 0.88–0.97). A significantly lower risk for chlamydia/gonorrhea was also found for observations during the COVID-19 pandemic period (OR 0.77, 95% CI 0.67–0.89). (Supplement Table 1).

The analysis of risk factors associated with infections among MSM with syphilis showed a significantly higher risk for persons 50–59 years of age (OR 1.33, 95% CI 1.01–1.75), with an STI history in the 6 months before PrEP start (OR 3.32, 95% CI 2.66–4.14) or an unknown STI history (OR 1.75, 95% CI 1.29–2.39), and with a higher number of symptom triggered tests for syphilis (OR 2.16, 95% CI 1.91–2.43). A significantly lower risk for syphilis was found for observations during the COVID-19 pandemic period (OR 0.71, 95% CI 0.54–0.93). (Supplement Table 2).

Hepatitis

In 3358 (72.7%) of individuals, hepatitis A immunity was reported, and 3664 (79.3%) had protection through antibodies against hepatitis B.

During the period of observation, two infections with hepatitis B were diagnosed on days 197 and 229 after start of observation, accounting for 0.043% of persons and an incidence rate of 0.04/100py (95% CI 0.01–0.16). Thirteen cases of hepatitis C were found at a median of 267 days (IQR 137–353) after start of observation in the study, and accounting for 0.28% of persons, a positivity rate of 0.30% (4273 tests) and an incidence rate of 0.25/100py (95% CI 0.15–0.44).

Additionally, one case of each, hepatitis A and B infection, and hepatitis C were diagnosed prior to or at the start of observation in the study (on days – 7, 0, and – 32 respectively).

Discussion

To our knowledge, this is the first comprehensive description and analysis of real-life PrEP use in the largest available population of PrEP users in Germany. The cohort of PrEP

users studied was predominantly male, MSM and in median 38 years of age. To estimate representativeness, we compared the demographic characteristics of our study population with health insurance data representing more than 50% of all persons with statutory health insurance in Germany and found them to be similar in gender, median age, PrEP use behavior, and regional distribution [21, 22]. To our knowledge, this is the only comparable source for Germany.

PrEP was found to be extremely effective in the prevention of HIV infection in this routine clinical setting. The observed incidence rate of 0.078/100py is comparable with and even lower than in other studies. The early iPrEX OLE study reported an HIV incidence of 1.83/100py and a strong protective effect with adequate drug levels. No HIV infection occurred in persons whose drug levels indicated an intake of four or more tablets per week [4]. More recently, the PROUD study found an incidence of 1.2/100py, the DISCOVER study an incidence of 0.34/100py in the TDF/FTC group and the IPERGAY study reported an incidence of 0.91/100py with on-demand TDF/FTC [23–25]. HIV incidence among PrEP users in implementation projects were closer to our findings with 0.16/100py in New South Wales (EPIC-NSW), 0.13/100py in England (PrEP Impact Trial), and 0.11/100py in France (ANRS PREVENIR) [26–28]. Differences in study populations and settings may partly explain differences in HIV incidence. In addition, our results are certainly influenced by the SARS-CoV-2 pandemic and the associated contact restrictions. However, a considerable rate of other sexually transmitted infections, shows that sexual contacts eventually took place during lockdown periods.

We found PrEP failure to be primarily linked to suboptimal adherence, which has been reported to be strongly correlated with efficacy [6, 29]. In our cohort, four persons were diagnosed with HIV while on PrEP. The person diagnosed on day 32 after PrEP initiation reported condomless rectal intercourse few days prior PrEP start and very likely was infected with HIV at baseline. In further two persons, acquisition of HIV infection was clearly linked to nonadherence. In one person failing on PrEP despite self-declared optimal adherence, resistance to FTC was documented. Yet, PrEP pill coverage for this person was calculated to be only 60%. And there were 5 months between the last negative and the first reactive HIV test. It, therefore, remains unclear whether this mutation was transmitted or selected for after transmission. Resistance to FTC is rare but well documented in persons with PrEP failure [6]. In addition, the presence of sexually transmitted infections may have facilitated HIV transmission in these persons [30].

The cohort of PrEP users studied was largely male, 99% MSM and 83% under the age of 50, which is similar to that in other implementation studies [26–28]. In Germany, PrEP appears to find minimal use outside the MSM community. This is supported by discussions with the community

advisory board that took place within the scope of the EvE-PrEP project [31–33]. Other groups that may benefit from PrEP include persons within trans*/non-binary communities, sex workers, and individuals with certain migratory backgrounds [21, 22]. The SARS-CoV-2 pandemic has further contributed to a reduced focus on prevention including promoting PrEP especially in non-MSM groups [13]. Making PrEP available by eliminating barriers and increasing access for people at risk requires further attention.

PrEP use was most commonly prescribed for daily intake, with intermittent/on-demand PrEP use reported by less than one quarter. However, the calculated PrEP pill coverage suggests slightly higher intermittent/on-demand use, in addition to suboptimal adherence to documented daily PrEP. PrEP interruptions and discontinuations were reported for 10% and 13%. Since 12% of PrEP users did not have any event related to PrEP use in the last two time periods of observation, possible interruption or discontinuation may not have been reported. The actual rate may, therefore, be higher up to around 20%. Approximately one-half of the PrEP interruptions occurred in March and April 2020 at the time of the first COVID-19 lock-down, and the reasons for PrEP discontinuations or interruptions were mainly SARS-CoV-2 related. Adverse reactions played only a minimal role, as seen in other studies [6, 23]. This highlights the need for education to enable people interested in PrEP to make an informed, evidence-based decision as well as potential for a more wide-spread use of PrEP, considering that the fear of adverse reactions was one of the main reasons not to start PrEP in several surveys [21, 22].

One major concern of PrEP availability is the potential for increasing sexual risk taking and hence for acquisition of sexually transmitted infections. Previous publications on trends in STI for Europe showed decreasing HIV incidences but increasing incidences for early syphilis, gonorrhea and chlamydia since 2014 which was partly explained by higher PrEP use [34]. At baseline, 20% of our study population had a history of an STI in the previous 6 months which is associated with an increased risk of HIV infection [35]. During the observation period, 37% of the study participants were reported to have had at least one STI with a total incidence of any STI of 55.4/100py, indicating that these persons were sexually very active and that PrEP was adequately prescribed to persons at risk. The observed incidences of STIs vary among studies and are in the range of 72.2/100py [20] to 105.4/100py [27] depending on the population studied. In comparison, the incidence rates of STIs in our study were lower than in the before mentioned international studies [8, 20, 27]. Yet, the overall proportion of persons with an STI diagnosis in our study was only slightly lower than in other studies. In a German nationwide, cross-sectional study conducted in 2018 before the start of PrEP coverage by health insurances any STI with chlamydia, gonorrhea,

Mycoplasma genitalium or *Trichomonas vaginalis* were documented for 25.0% of HIV-/PrEP- MSM and 40.3% in HIV-/PrEP+ MSM [36]. In an Australian intervention study, 48% of participants were diagnosed with chlamydia, gonorrhea, or syphilis during a mean follow-up of 1.1 years [8]. While some evaluations showed an increase of STI infection rates during PrEP use over time [37], we found a significant decrease. This decrease is certainly in part attributable to the SARS-CoV-2 pandemic and the measures taken to control it as confirmed in the regression model. Yet, counselling and creating awareness as part of PrEP care may have also played a role.

The SARS-CoV-2 pandemic had a drastic influence on social behavior and sexuality. Yet sexual contacts in private settings took place with equal risk of HIV transmission. Sentis et al. found a 56% reduction in STIs during the March/April lockdown in Spain [38]. It was concluded that the decline probably was due to the effect of a combination of factors including change in sexual behavior as well as decreased availability of resources and decreased use of health care [38]. An analysis of notifiable STI case reports during the COVID-19 pandemic for 2020 in the US showed a clearly decreasing incidence of STIs during the strict lockdown time, but higher incidences thereafter for syphilis and gonorrhea [39].

Interestingly, in our study, rates over time also differed between STIs. Infections with chlamydia decreased with the lockdowns in the second and fourth quarters of 2020 and increased with social opening in the third quarter. After the initial decrease, infections with gonorrhea, on the other hand, showed a steady increase in both the third and the fourth quarters. Infections with Syphilis differed again, with their nadir in the third quarter, likely reflecting its longer incubation time [40, 41], followed by a slight rise in the fourth quarter of 2020. The incidence of Syphilis infections was slightly higher when compared to other studies [8, 27].

When evaluating infection rates, it is important to consider testing rates. Testing for chlamydia/gonorrhea decreased in the second and fourth quarters, which may reflect the pandemic lockdowns. Syphilis testing was higher throughout and decreased over the course of 2020. Interestingly although numbers of tests differed, the positivity rates remained relatively constant. Other investigators have reported decreased testing for other infections, reduced use of health care as well as a marked reduction of spread of communicable diseases, including STI and HIV, in times of social lockdown [42, 43]. In Germany, a drastic decline of notifications for most infectious diseases and pathogens was observed [44]. Of our study centers, 76% reported a decrease of requests for PrEP and 60% said PrEP check-ups were skipped during the first lockdown of the pandemic [13]. The COVID-19 pandemic and the measures taken to control

it certainly influenced the results and outcomes of our study as confirmed in the regression model.

While almost one-half of chlamydia and gonorrhea infections were a result of screening of asymptomatic persons, this was the case for two-thirds of syphilis infections. The high rate of syphilis found solely by screening asymptomatic MSM highlights its importance in the prevention of transmission. The lower testing numbers for chlamydia/gonorrhea appear to reflect the differing approaches taken by physicians and the controversies surrounding testing and treating of asymptomatic individuals [14, 45].

The significantly higher risk of infection with chlamydia/gonorrhea for MSM aged 16–29 years and the significantly lower risk for MSM aged 40–59 years when compared to 30–39 years may reflect higher sexual activity and more partners in younger age groups. Unexpectedly, age 50–59 years was associated with an increased risk for syphilis. This finding is not supported by the national mandatory syphilis reports, which show the highest incidence for men between 30–39 years of age [46]. Further analysis in terms of study center location indicated that there may be an interrelated infection pattern that possibly explains this discrepancy.

A higher risk for chlamydia/gonorrhea was found in MSM with PrEP start before its coverage by statutory health care in September 2019. It likely reflects these individuals' involvement in the sexually active MSM community. In addition, this indicates persistent HIV risk behavior, which goes along with infection risks of other STIs. The lower risk for chlamydia/gonorrhea seen with intermittent/on-demand PrEP use, on the other hand, may in turn reflect less frequent high-risk sexual contacts.

The lower risk for chlamydia/gonorrhea and syphilis during the COVID-19 pandemic period was likely caused by a number of factors as discussed above.

As expected, symptom triggered testing and a history of STI was associated with a higher risk for infections with chlamydia/gonorrhea and syphilis. The latter supports the importance of comprehensive history taking before PrEP initiation.

We found a high baseline protection against hepatitis A and B in approximately three-quarters of the cohort. Of note, immunity against hepatitis A may be in part self-reported and the actual percentage therefore lower supporting the call for serologic testing of immunity against hepatitis A prior to PrEP initiation. However, this is not covered by the German statutory health insurance nor recommended by the German/Austrian PrEP guidelines. Hepatitis B virus infection status on the other hand should routinely be determined prior to commencing PrEP according to the German/Austrian PrEP guideline due to the interaction between tenofovir and hepatitis B [47]. Accordingly, no infection with hepatitis A and only two with hepatitis B were diagnosed within the course of the study. However, thirteen cases of hepatitis C occurred,

reflecting an ongoing epidemic of sexually transmitted hepatitis C among MSM, which in the past was almost exclusively seen among HIV infected MSM [48]. Additionally, at screening before PrEP initiation one case of each hepatitis A, B, and C were detected underlining the importance of a medically guided PrEP start.

Our study has several limitations: the evaluation period of sixteen months limits the ability to determine HIV and STI trends over time. Furthermore, detecting a hepatitis B/C infection can take several months after transmission. However, most of the participants were followed for a longer period with a median of 451 days within the observation period. The predefined four weeks for PrEP interruptions may have led to an underestimation of shorter PrEP interruptions. Also, the SARS-CoV-2 pandemic drastically affected social interaction and influenced the outcomes found in this study. Further investigation in a regular non-pandemic setting with a longer follow-up period would be valuable. The number of partners or sexual behaviors were not documented due to the retrospective chart review design of our study. Our population does not include all PrEP-users in Germany, nor all PrEP prescribing centers. For budgetary reasons participating centers could not document all PrEP users and were asked to include a random sample of their PrEP users into the study, however, no formal randomization process was implemented. This may have led to a selection bias. However, the fact that PrEP care is provided primarily by HIV-specialty care centers, many of which participated in this study with a German wide distribution and experience in clinical studies, lead us to assume that a representative sample was obtained. More than one-third of HIV-positive people receiving treatment in Germany and one-fourth of all PrEP users in Germany were cared for in the study centers [12, 14]. In addition, to estimate representativeness, the characteristics of PrEP users in NEPOS were compared with routine health insurance data analyzed in EvE-PrEP and were found to be similar.

Conclusions

In Germany, HIV-PrEP with TDF/FTC is almost exclusively taken by MSM. We found a very low incidence of HIV infection in this cohort of PrEP users comparable to implementation projects in other countries. The main reason for PrEP failure was suboptimal adherence. We did not see an increase in infections with chlamydia, gonorrhea and syphilis; in fact, we saw a partial decrease in their incidence rates. The COVID-19 pandemic certainly influenced the findings of our study. Our results support the coverage of PrEP medication and care by statutory health insurance. Increased PrEP availability to people at risk for HIV infection through

the elimination of barriers and improved access requires further attention. Further investigation and monitoring with a longer follow-up would be of value.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s15010-022-01919-3>.

Acknowledgements The authors are grateful to the PrEP users and to all collaborative NEPOS centers for the data collection and study management in the centers. The authors would like to thank Andrea Sailer for her assistance in the preparation of Fig. 1 and Matthias an der Heiden for his support with the logistic regression analyses. We thank all cooperating partners in EvE-PrEP.

The NEPOS study group: Aachen: Heribert Knechten, Petra Panstruga (Praxis Dr. Knechten, Aachen); Berlin: Axel Baumgarten, Bianca Reisenweber (Zentrum für Infektiologie Berlin Prenzlauer Berg, ZIBP, Berlin); Heribert Hillenbrand, Kai Zucker (MVZ Praxis City Ost, Berlin); Siegfried Köppe, Marc Da Silva Ribeiro, (Internistische GP Dres. Köppe und Kreckel, Berlin); Ivanka Krznaric, Denis Pitan (Praxis an der Kulturbrauerei, Berlin); Christian Lieb, Hussien Yasin (Praxis Goldstein, Berlin); Ingo Ochlast, Irina Shurenko (Praxisteam Friedrichshain, Berlin); Michael Rausch, Svetlana Krasov (MVZ Praxis Schöneberg, Berlin); Sven Schellberg, Peter Stueber (Novopraxis, Berlin); Dietmar Schranz, Michael Rittweger (Praxis Wilmersdorfer Dres. Schranz, Fischer und Rittweger, Berlin); Hubert Schulbin, Adam Smiley (Praxis Kreuzberg, Berlin); Kevin Ummard-Berger, Andreas Berger (UBN Praxis, Berlin); Johannes Lenz (Praxis Turmstraße, Berlin); Bonn: Christoph Boesecke, Martha Oberschlep (Uniklinik Bonn, Ambulanz für Infektiologie & Immunologie Med. Klinik und Poliklinik, Bonn); Bremen: Susann Koch, Mareen Monsees (Praxis für Onkologie und Infektiologie, Bremen); Chemnitz: Thomas Heuchel, Manuela Richter (Praxis Dr. Heuchel, Chemnitz); Dortmund: Andreas Bellmunt-Zschäpe, Jutta Hahn (Praxis Bellmunt Zschäpe, Dortmund); Dresden: Andreas Jenke, Stefan Pursche (Praxis Dr. Jenke, Dresden); Düsseldorf: Stefan Mauss, Florian Berger (MVZ für Leber-, Magen-, Darm, Infektions- und Krebserkrankungen, Düsseldorf); Frankfurt: Marcus Bickel, Monja Rößler, (Infektiologikum Frankfurt, Frankfurt); Anette Haberl, Peter Schott (HIVCENTER Klinikum der Johann Wolfgang-Goethe-Universität Zentrum der Inneren Med. II, Frankfurt), Pavel Khaykin, Michaela Bracone (GP Dres. Manfred Mösch und Pavel Khaykin, Frankfurt); Freiburg: Susanne Usadel, Tina Mattmüller (Zweigpraxis der MVZ Clotten GbR, Freiburg). Gießen: Georg Friese, Ulrike Kratz (Dr. med. Cseke und Dr. med. Friese Hausärztlich Internistische GP, Gießen). Hamburg: Sandra Hertling, Dirk Berzow (Praxisgemeinschaft Dr. Dirk Berzow, Andreas Christl und Dr. Sandra Hertling, Hamburg); Knud Schewe, Constantin Rickassel ICH Hamburg–Stendal GbR/ ICH Stadtmitte, Hamburg); Hannover: Hans Heiken (Praxis Georgstraße, Hannover). Koblenz: Ansgar Rieke, Petra Becker (Gemeinschaftsklinikum Mittelrhein gGmbH, Akademisches Lehrkrankenhaus der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Kemperhof, Immunologische Ambulanz, Koblenz); Köln: Katja Römer, (GP Gotenring, Köln); Stefan Scholten, Andreas Roder (Praxis Hohenstaufenring Dr. Scholten & Schneeweiß GbR, Köln); Christoph Wyen, Kerstin Lammersmann (Praxis am Ebertplatz, Köln); Leipzig: Ines Ruck (Praxis Dr. med. Ines Ruck, Leipzig); Mainz: Burkhard Schappert (Allgemeinmedizinische Praxis Prof. Dr. B. Schappert, O. Gangaev, Mainz); München: Ulrich Kastenbauer (Praxis Dr. Ulrich Kastenbauer, München); Ramona Pauli, Oskar Mikazans (Isarpraxis Dres. Becker, Pauli, Lee und Dialer, München); Farhad Schabaz (MVZ München am Goetheplatz, München); Christoph Spinner, Stefanie Gladis (Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar der TUM, München); Münster: Stefan Christensen, Sabine Offermann (Infektiologische Praxisgemeinschaft Dr. med. H. W. Busch, Dr. med. St. Christensen, Münster); Neuss: Robert Baumann (GP Dr. med. R. Baumann und Dr. med. Florian Sels, Neuss);

Osnabrück: Niels Schübel, Anja Lüssenheide, (Klinikum Osnabrück, infektiologisches Zentrum, Osnabrück); Regensburg: Franz Audebert, Elisabeta Sepsy (Praxiszentrum Alte Mälzerei, Regensburg); Saarbrücken: Beatrice Gospodinov, Aynur Bulut (GP für Allgemeinmedizin Béatrice Gospodinov & Katarina Projsner, Saarbrücken); Stuttgart: Patrick Beck, Jennifer Weida (GP Schwabstrasse 59, Stuttgart); Ulm: Georg Härter, Petra Schütz (Medicover Ulm MVZ, Ulm); Weimar: Thomas Seidel (MEDCENTER Weimar, Dr. med. Seidel Innere Medizin, hausärztl. Versorgung, Infektiologie, Weimar); Wuppertal: Sabine Mauruschat (Praxis für Allgemein- und Suchtmedizin, Substitutionsbehandlungen und Infektiologie, Wuppertal). Zwickau: Steve Rößler, (Arztpraxis Steve Rößler, Zwickau).

Author contributions DS was responsible for the study design, performed the data analysis and statistical analysis, interpreted the data and drafted the manuscript. CK contributed to the conception of the study and interpretation of the data and was responsible for the data management. KS, RR and NH contributed to the conception and coordination of the study and interpretation of the data and to draft the manuscript. MF and TS supported the management and coordination of the study and contributed to improving the data quality and coverage. SS, SVS, MB are site principal investigators, contributed data and supported the interpretation of the data. VB and BB supported the management and coordination of the study and the overall study design and analysis approach. All authors participated in the critical discussion of the results, and all read and approved the final manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. The PrEP evaluation (EvE-PrEP) was funded by the Federal Ministry of Health, Germany. We acknowledge the financial support of the German Federal Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials The datasets generated and/or analyzed during the current study are not publicly available due to data protection and confidentiality but are available from the corresponding author on reasonable request.

Declarations

Conflict of interest DS, MF, BB, VB, TS, MB, RR, KS, and NH declare that they have no competing interests. CK is small shareholder in companies manufacturing antiretroviral drugs. SS has received honoraria for lectures, conference sponsorship and participation on advisory boards from Abbvie, Gilead, Janssen, GSK, MSD, ViiV Healthcare, Theratechnologies. SVS has received honoraria and study compensation from companies developing and marketing antiretroviral drugs and is shareholder of various pharmaceutical companies including ones developing and marketing antiretroviral drugs. KS has received honoraria for lectures, conference sponsorship and participation at advisory boards from Abbvie, Gilead, Janssen, MSD, ViiV Healthcare, Hexal.

Ethics approval and consent to participate All patient data collected in NEPOS were generated during routine care. The data collected were anonymous. No direct patient survey or sampling took place within NEPOS. No human samples were collected and sent to the RKI. The Ethics Committee of the Berlin Chamber of Physicians reviewed the project and waived the need for ethical approval or informed consent, as it involves only retrospective anonymous data (Eth-KB 03/20). We confirm that all methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Global HIV & AIDS statistics—Fact sheet [Internet] 2021 [2021 Oct 6]. <https://www.unaids.org/en/resources/fact-sheet>.
- Heiden Mad, Marcus U, Kollan C, Schmidt D, Gunsenheimer-Bartmeyer B, Bremer V. chätzung der Zahl der HIV-Neuinfektionen im Jahr 2020 und der Gesamtzahl von Menschen, die Ende 2020 mit HIV in Deutschland leben. *Epidemiologisches Bulletin* 2021;47
- Schmidt D, Kollan C, Stoll M, Hamouda O, Bremer V, Kurth T, et al. Everything counts—a method to determine viral suppression among people living with HIV using longitudinal data for the HIV care continuum—results of two large, German, multi-center real-life cohort studies over 20 years (1999–2018). *BMC Public Health*. 2021;21:1–17.
- Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. *Lancet Infect Dis*. 2014;14:820–9.
- Bailey JL, Molino ST, Vega AD, Badowski M. A review of HIV pre-exposure prophylaxis: the female perspective. *Infect Dis Ther*. 2017;6:363–82.
- Riddell J, Amico K, Mayer K. HIV preexposure prophylaxis: a review. *JAMA*. 2018;319:1261–8.
- Werner R, Gaskins M, Nast A, Dressler C. Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection—a meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. *PLoS ONE*. 2018;13: e0208107.
- Traeger M, Cornelisse V, Asselin J, Price B, Roth N, Willcox J, et al. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. *JAMA*. 2019;321:1380–90.
- Barreiro P. Sexually transmitted infections on the rise in PrEP users. *AIDS Rev*. 2018;20:71.
- European Medicines Agency (EMA). First medicine for HIV pre-exposure prophylaxis recommended approval in the EU [Internet] 2018 [2021 Oct 6]. <https://www.ema.europa.eu/en/news/first-medicine-hiv-pre-exposure-prophylaxis-recommended-approval-eu>.
- GKV-Spitzenverband, Anlage 33 Bundesmantelvertrag Ärzte (BMV-Ä) Anlage_33_PreP_24-7-2019.pdf [Internet] [2021 Oct 6]. https://www.gkv-spitzenverband.de/media/dokumente/krankensversicherung_1/aerztliche_versorgung/bundesmantelvertrag_1/bmv_anlagen/BMV-Ae_Anlage_33_PreP_24-7-2019.pdf.
- Marcus U, Schmidt D, Schink SB, Koppe U. Analysis of HIV pre-exposure prophylaxis (PrEP) needs and PrEP use in Germany among men who have sex with men. *J Public Health*. 2022. <https://doi.org/10.1007/s10389-022-01699-y>.
- Schmidt D, Merbach M, Friebe M, Hanhoff N, Rösenberg R, Schewe K. Wissenschaftliche Begleitung und Evaluation der HIV-PrEP als Leistung der gesetzlichen Krankenversicherung – das Projekt EvE-PrEP in Zeiten der SARS-CoV-2-Pandemie. *Epidemiologisches Bulletin*. 2021;06:3–12.
- Schmidt D, Schikowski T, Friebe M, Kollan C, Bartmeyer B, Bremer V, et al. PrEP-Evaluation EvE-PrEP – Ergebnisse einer Befragung zum PrEP-Versorgungsgeschehen in HIV-Schwerpunktzentren des dagnä-Netzwerks. *Epidemiologisches Bulletin*. 2021;44:3–12.
- Schmidt D, Rösenberg R. HIV-Präexpositionsprophylaxe: Einführung der PrEP wird wissenschaftlich begleitet. *HIV More*. 2019;04:24–5.
- Schmidt D, Schikowski T, Friebe M, Kollan C, Bartmeyer B, Bremer V, et al. PrEP-Evaluation (EvE-PrEP) - Ergebnisse einer Befragung zum PrEP-Versorgungsgeschehen in HIV-Schwerpunktzentren des dagnä-Netzwerks. *HIV More*. 2021;4
- Schmidt D. Evaluation der Einführung der HIV-PrEP als Leistung der gesetzlichen Krankenversicherung “EvE-PrEP” - PrEP in Berlin. *Fast Track City Summit 2021*; Berlin, Germany 2021.
- Schmidt D. Evaluation der Einführung der HIV-Präexpositionsprophylaxe als Leistung der Gesetzlichen Krankenversicherung (EvE-PrEP) 2022 [updated Stand: 22.06.2022]. <https://www.rki.de/eve-prep>.
- Deutsch-Österreichische Leitlinien zur HIV-Präexpositionsprophylaxe, (2018).
- Ong J, Baggaley R, Wi T, Tucker J, Fu H, Smith M, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. *JAMA*. 2019;2: e1917134.
- Schmidt D. Kurzbericht - Evaluation der Einführung der HIV-Präexpositionsprophylaxe als Leistung der Gesetzlichen Krankenversicherung (EvE-PrEP). *Robert Koch Institute 2022* 23.02.2022.
- Schmidt D, Bartmeyer B, Bremer V, Friebe M, Schikowski T, Schink SB, et al. Abschlussbericht - Evaluation der Einführung der HIV-Präexpositionsprophylaxe als Leistung der Gesetzlichen Krankenversicherung (EvE-PrEP). *Robert Koch-Institut*; 2022 22.06.2022.
- Mayer KH, Molina J-M, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. *Lancet Lond Engl*. 2020;396:239–54.
- McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet*. 2016;387:53–60.
- Molina J-M, Capitán C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. *N Engl J Med*. 2015;373:2237–46.
- Grulich AE, Jin F, Bavinton BR, Yeung B, Hammoud MA, Amin J, et al. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. *Lancet HIV*. 2021;8:e486–94.
- Sullivan R, Chiavenna C, Cartier A, Jaffer S, et al. HIV and STI incidence among MSM users and non-users of HIV PrEP in England: results from the Impact trial - Preliminary Report. 18th European AIDS Conference. 2021.
- Molina J-M, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, et al. Daily and on-demand HIV pre-exposure

- prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. *Lancet HIV*. 2022;9:e554–62.
29. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010;363:2587–99.
 30. Hoornenborg E, Prins M, Achterbergh RC, Woittiez LR, Cornelissen M, Jurriaans S, et al. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. *Lancet HIV*. 2017;4:e522–8.
 31. Schmidt D. Bericht zur 2. virtuellen Sitzung der Community-Vertretungen zur Evaluation der Einführung der medikamentösen HIV-Präexpositionsprophylaxe als Leistung der GKV (EvE-PrEP). Berlin: Robert Koch-Institut; 2020.
 32. Schmidt D. Bericht zur 1. Sitzung der Community-Vertretungen zur Evaluation der Einführung der medikamentösen HIV-Präexpositionsprophylaxe als Leistung der GKV (EvE-PrEP). Berlin: Robert Koch-Institut; 2020.
 33. Schmidt D. Bericht zur 3. virtuellen Sitzung der Community-Vertretungen zur Evaluation der Einführung der medikamentösen HIV-Präexpositionsprophylaxe als Leistung der GKV (EvE-PrEP). Berlin: Robert Koch-Institut; 2021.
 34. Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, et al. Sexually transmitted infections: challenges ahead. *Lancet Infect Dis*. 2017;17:e235–79.
 35. White E, Dunn D, Desai M, Gafos M, Kirwan P, Sullivan A, et al. Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial. *Sex Transm Infect*. 2019;95:449–54.
 36. Jansen K, Steffen G, Potthoff A, Schuppe AK, Beer D, Jessen H, et al. STI in times of PrEP: high prevalence of chlamydia, gonorrhoea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. *BMC Infect Dis*. 2020;20:110.
 37. Serpa JA, Huynh GN, Nickell JB, Miao H. Human immunodeficiency virus pre-exposure prophylaxis and increased incidence of sexually transmitted infections in the United States. *Clin Infect Dis*. 2020;70:1884–90.
 38. Sentís A, Prats-Urbe A, López-Corbeto E, Montoro-Fernandez M, Nomah D, de Olalla P, et al. The impact of the COVID-19 pandemic on Sexually Transmitted Infections surveillance data: incidence drop or artefact? *BMC Public Health*. 2021;21:1637.
 39. Pagaoa M, Grey JF, Torrone E, Torrone E, Fau - Kreisel K, Kreisel KF, Stenger M, Stenger M, Fau - Weinstock H, Weinstock H. Trends in Nationally Notifiable Sexually Transmitted Disease Case Reports During the US COVID-19 Pandemic, January to December 2020. (1537–4521 (Electronic)).
 40. Esser S, Ulrich M. Syphilis/Lues [2021 Dec 2]. <https://www.hivandmore.de/sti/syphilis.shtml>.
 41. Peterman TA, Heffelfinger JD, Swint EB, Groseclose SL. The changing epidemiology of syphilis. *Sex Transm Dis*. 2005;32:S4–10.
 42. New South Wales Ministry of Health (NSW). Sexually Transmissible Infections Strategy 2016–2020: Data Report January to December 2020. 2020.
 43. Cowling BJ, Ali ST, Ng TW, Tsang TK, Li JC, Fong MW, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. *Lancet Public Health*. 2020;5:e279–88.
 44. Ullrich A, Schranz M, Rexroth U, Hamouda O, Schaade L, Diercke M, et al. Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: an analysis of national surveillance data during week 1–2016 - week 32–2020. *Lancet Regional Health Europe*. 2021;6:100103.
 45. Schafberger A. STI: Wir testen zu viel! 2020 [2021 Dec 2]. <https://www.hivandmore.de/archiv/2020-1/sti-wir-testen-zu-viel.shtml>.
 46. Robert Koch-Institut - Syphilis in Deutschland im Jahr 2019 – Neuer Höchststand von Infektionen. *Epidemiologisches Bulletin*. 49/2020:3–13
 47. European Association for the Study of the Liver. EASL 2017. Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol*. 2017;67(2):370–98.
 48. Jansen K, Thamm M, Bock C-T, Scheufele R, Kücherer C, Muenstermann D, et al. High prevalence and high incidence of coinfection with hepatitis B, hepatitis C, and syphilis and low rate of effective vaccination against hepatitis B in HIV-positive men who have sex with men with known date of HIV seroconversion in Germany. *PLoS ONE*. 2015;10: e0142515.
 49. Sahai H, Khurshid A. Statistics in epidemiology: methods, techniques and applications. 1995.

Authors and Affiliations

Daniel Schmidt¹ · Christian Kollan¹ · Barbara Bartmeyer¹ · Viviane Bremer¹ · Tim Schikowski¹ · Martin Friebe¹ · Sven Schellberg² · Stefan Scholten³ · Markus Bickel⁴ · Nikola Hanhoff⁵ · Robin Rösenberg⁵ · Knud Schewe⁵ · The NEPOS study group

¹ Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

² Novopraxis, Berlin, Germany

³ Praxis Hohenstaufenring, Cologne, Germany

⁴ Infektiologikum, Frankfurt, Germany

⁵ German Association of Physicians in HIV-Care (dagnä e.V.), Berlin, Germany